Keywords: japanese, indian, feature, pharma/biotech, deals, saw, increase
Japanese and Indian M&As feature in 2005 pharma/biotech deals
Article | 09 January 2006
2005 saw an increase in global merger and acquisition activity, with the value of worldwide, all-industry deals reaching a $2,900.0 billion high, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
